Artificial intelligence (AI) is steadily reshaping healthcare from all sides, introducing technologies we wouldn't have thought possible five or 10 years ago. It's happening in the clinic (see HealthTap's Doctor A.I.), it's happening in diagnostics (see IBM Watson), and now it's moving into earlier-stage drug discovery with Palo Alto, California-based twoXAR. "In the couple years that we have been around, we've been told hundreds of times that computers cannot do this; that biology is too complex; that this will never work," said Andrew A. Radin, CEO of the AI-driven biopharmaceutical company. "Yet, in every single disease program where we have run proof-of-concept studies on our novel AI-identified candidates, we have generated efficacious results across standard end points." Using a custom-built computational platform, twoXAR works to identify what it calls "unanticipated associations between drug and disease."

AliveCor, which has developed an FDA-cleared smartphone-enabled ECG device, has launched a clinician-facing app using artificial intelligence to pick up signs of atrial fibrillation earlier, according to a company news release. It's an interesting development for the business because it can alert physicians to patients with an elevated risk of having a stroke. The Kardia Pro app is for clinical use. But the goal is to analyze data from patients that includes weight, activity and blood pressure with AI to personalize the heart profiles of each patient, the news release said. An estimated 795,000 people suffer a stroke each year, the majority of them for the first time.

Technically it ain't brain surgery, but let's just say you wouldn't want to do a cochlear implant while sleepy or distracted. So it's a good thing this surgery robot can't be either of those things. The bit passes just half a millimeter from the facial nerve, and another half a millimeter from the taste nerve, before entering the spiraling cochlea of the inner ear. The first robot-assisted cochlear implant in a clinical trial, which researchers describe today in the journal Science Robotics, doesn't just enhance a surgeon's dexterity like the by-now-common da Vinci robot might. "We are interested in doing something with the robot that a surgeon is not able to do," says study co-author Stefan Weber of the ARTORG Center for Biomedical Engineering Research.

BenevolentBio's CMO, Dr Patrick Keohane, says the industry is on the cusp of an artificial intelligence (AI) revolution… Medical research is entering a period of rapid transformation, driven by the explosion of scientific data, rapid advances in artificial intelligence (AI), and the development of extremely powerful computers. This convergence enables researchers to access enormous and diverse datasets to rapidly form and test scientific hypotheses. It is disrupting the way we identify, validate, and transform scientific concepts into potential Healthcare solutions – ultimately revolutionising the scientific process. AI enables access and the more effective use of existing information for the discovery and development of better drugs at a speed previously unimagined. This is helping to meet the high demand from society to provide better medicines at a reasonable cost, but also influencing how we are looking to treat rarer forms of disease.

Medicine is a complex field. So complex that any given person can't know more than a fraction of what's going on. Keeping up with the latest discoveries is impossible. At the South by Southwest conference event in Austin, TX, a panel of experts came together to discuss the state of medical AI and how machine learning can benefit both patients and doctors. The discussion was moderated by Kay Eron, general manager of health and life sciences at Intel.

As I start to look at the emerging trends of 2017 from the vantage of IndieBio, where we see hundreds of biotech startup applications and technologies per year, a few key themes are already emerging. Even as political landscapes change, science and technology continue to push forward. Most of us have seen science fiction shows that show future doctors regrowing and replacing entire organs. That fiction is now becoming a reality with cell therapies from companies like Juno (curing two infants with leukemia of their previously treatment resistant cancers with engineered T-cells), induced pluripotent stem cells (iPS) pioneered by the Nobel prize winning scientist, Shinya Yamanaka that can become any cell in the body, growing organoids (mini organs with some function of a fully grown organ like the stomach organoids grown by researchers in Ohio), and entirely re-grown organs. There are a plethora of biotechs focused on developing the next generation of regenerative therapies.

Ubisoft Senior Producer Mathieu Ferland demonstrates Dig Rush, created by Ubisoft and Amblyotech to be the first therapeutic video game used for the treatment of'lazy eye.' (Photo: Josh Edelson/AFP/Getty Images) "Make sure you play your video game," is not something you commonly hear parents say to kids. But Amblyotech's Amblyopad device armed with Ubisoft's video games Dig Rush and Monster Burner may change this...at least in some households. Amblyotech just filed for U.S. Food and Drug Administration (FDA) approval for these games to help treat "lazy eye," which is the lazier way of saying amblyopia. Amblyopia is when the one of your eye's vision is reduced because, as the National Eye Institute (NEI) describes, "the eye and the brain are not working together properly." In this condition which affects 3% of children, your brain favors using one eye over the other (assuming that you only have two eyes), perhaps because your eyes are misaligned (also called strabismus) or the vision in one eye is impaired.

Imaging and understanding the brain is getting so good we are on the cusp of truly enhancing it. This article originally appeared on SOSV.) As I start to look at the emerging trends of 2017 from the vantage of IndieBio, where we see hundreds of biotech startup applications and technologies per year, a few key themes are already emerging. Even as political landscapes change, science and technology continue to push forward. Most of us have seen science fiction shows that show future doctors regrowing and replacing entire organs.

In mobile marketplaces like the Apple App Store or the Google Play Store, there are thousands of apps that help track or care for personal health. And by and large, consumers have been big fans of these apps. According to an estimate from the Food and Drug Administration (FDA), more than 500 million smartphone users are actively using a health care-related application. And, according to the FDA's projections, more than 1.5 billion smartphone users will have downloaded a mobile health app by 2018. While these apps may enable users to take better care of their personal health, because they are designed for use by a mass audience, they often lack the personalization and one-on-one experience that health care typically requires.

Artificial Intelligence already had a massive impact in the past years, but where will AI be in the coming years? Here is a list of predictions. Waiting to make their moveAsia's looming labour shortage p There is an obvious solution p print-edition iconFrom the print edition Asia p Feb 11th 2017 p THE … The first FDA approval for a machine learning application to be used in a clinical setting is a big step forward for AI and machine learning in healthcare and industry as a whole. Until recently, artificial intelligence (AI) was similar to nuclear fusion in unfulfilled promise. ManpowerGroup, one of the world's largest jobs companies, released a report detailing how the technological revolution is going to change the … Replacing the real world with a virtual one is a neat trick.